LongevityNext

Global Longevity Intelligence

Longevity intelligence for people who need to separate signal from hype.

Track companies, interventions, trials, biomarkers, clinics, deals, and regulation through an evidence-first scorecard model.

Entity Evidence Risk
Clinic model2/53/5
Biomarker panel2/52/5
Trial endpoint3/51/5
Scorecards organize evidence and risk across reviewed longevity categories.

Evidence Watch

View all
Reports Sample / unverified

Evidence Watch: Aging Biomarkers (Sample)

Sample report profile for evidence-watch briefings.

LN Evidence Score 2 of 5
LN Claim Risk Score 2 of 5
LN Commercial Maturity Score 2 of 5
LN Clinic Transparency Score 0 of 5
Reports Sample / unverified

Market Map: Longevity Clinics (Sample)

Sample report record for the clinic intelligence section.

LN Evidence Score 1 of 5
LN Claim Risk Score 2 of 5
LN Commercial Maturity Score 3 of 5
LN Clinic Transparency Score 2 of 5

Company Radar

View all
Companies Source-reviewed

University of Birmingham

LN Evidence Score N/A Pending review
LN Claim Risk Score N/A Pending review
LN Commercial Maturity Score N/A Pending review
LN Clinic Transparency Score N/A Pending review
Companies Source-reviewed

Cambrian Bio

LN Evidence Score N/A Pending review
LN Claim Risk Score N/A Pending review
LN Commercial Maturity Score N/A Pending review
LN Clinic Transparency Score N/A Pending review
Companies Source-reviewed

University of Copenhagen

LN Evidence Score N/A Pending review
LN Claim Risk Score N/A Pending review
LN Commercial Maturity Score N/A Pending review
LN Clinic Transparency Score N/A Pending review

Trial Tracker

View all
Trials Source-reviewed

UBX0101 Phase 2 knee osteoarthritis

LN Evidence Score N/A Pending review
LN Claim Risk Score N/A Pending review
LN Commercial Maturity Score N/A Pending review
LN Clinic Transparency Score N/A Pending review
Trials Source-reviewed

Dasatinib plus quercetin bone-metabolism trial

LN Evidence Score N/A Pending review
LN Claim Risk Score N/A Pending review
LN Commercial Maturity Score N/A Pending review
LN Clinic Transparency Score N/A Pending review

Biomarker Watch

View all
Biomarkers Source-reviewed

VO2max / cardiorespiratory fitness

LN Evidence Score N/A Pending review
LN Claim Risk Score N/A Pending review
LN Commercial Maturity Score N/A Pending review
LN Clinic Transparency Score N/A Pending review
Biomarkers Source-reviewed

Leukocyte telomere length

LN Evidence Score N/A Pending review
LN Claim Risk Score N/A Pending review
LN Commercial Maturity Score N/A Pending review
LN Clinic Transparency Score N/A Pending review
Biomarkers Source-reviewed

Retinal age gap

LN Evidence Score N/A Pending review
LN Claim Risk Score N/A Pending review
LN Commercial Maturity Score N/A Pending review
LN Clinic Transparency Score N/A Pending review

Global Clinic Intelligence

View all
Clinics Sample / unverified

Executive Longevity Clinic Model (Sample)

Sample profile for a high-touch clinic model with limited published outcomes.

LN Evidence Score 1 of 5
LN Claim Risk Score 3 of 5
LN Commercial Maturity Score 4 of 5
LN Clinic Transparency Score 2 of 5
Clinics Sample / unverified

Transparent Longevity Clinic Model (Sample)

Sample clinic profile for testing transparency scoring.

LN Evidence Score 1 of 5
LN Claim Risk Score 2 of 5
LN Commercial Maturity Score 3 of 5
LN Clinic Transparency Score 4 of 5

Regulation & Policy

View all
Regulations Source-reviewed draft

Longevity Clinic Advertising Review

Regulatory watch draft for longevity, regenerative, and clinic advertising claim-risk patterns. Staging only; not legal advice.

LN Evidence Score 0 of 5
LN Claim Risk Score 4 of 5
LN Commercial Maturity Score 2 of 5
LN Clinic Transparency Score 0 of 5
Regulations Source-reviewed draft

Consumer Biomarker Claims Watch

Regulatory watch draft for consumer biomarker and direct-to-consumer test claim-risk context. Staging only; not legal advice.

LN Evidence Score 0 of 5
LN Claim Risk Score 3 of 5
LN Commercial Maturity Score 2 of 5
LN Clinic Transparency Score 0 of 5

LN Pro

Scorecards, trackers, alerts, and analyst briefings for professional users.

Request access
Opens in a new tab